Nxera Pharma Co., Ltd. (TYO:4565)
Japan flag Japan · Delayed Price · Currency is JPY
1,677.00
-68.00 (-3.90%)
Nov 18, 2026, 10:50 AM JST

Nxera Pharma Cash Flow Statement

Millions JPY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-5,393-14,950-4,662-10,6801,078433
Depreciation & Amortization
4,3454,3663,9842,4781,3451,278
Loss (Gain) From Sale of Assets
-1,160---3,138
Loss (Gain) From Sale of Investments
--51,3631,877-208
Loss (Gain) on Equity Investments
28---429-50
Other Operating Activities
3,7581,45028-942338486
Change in Accounts Receivable
810-1,039-7421,315-210-799
Change in Inventory
-2,169-2,456-5,9351,908--
Change in Accounts Payable
-1,0882,971-4871,552315-184
Change in Other Net Operating Assets
2,1575,83091-2,2674,7803,001
Operating Cash Flow
5,603-2,668-7,718-5,2739,9527,095
Operating Cash Flow Growth
----40.27%51.86%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-590-448-526-804-277-193
Cash Acquisitions
----62,941--
Divestitures
-----206
Sale (Purchase) of Intangibles
-5,257-177-1,011-47-26-8
Investment in Securities
3,6626,028-3,870-1,209-
Other Investing Activities
-69276441137273
Investing Cash Flow
-2,2545,430-4,763-63,7911,043278

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
---71,608-29,855
Long-Term Debt Repaid
--15,139-5,800-1,450--
Total Debt Repaid
-16,040-15,139-5,800-1,450--
Net Debt Issued (Repaid)
-16,040-15,139-5,80070,158-29,855
Issuance of Common Stock
---9,983-600
Other Financing Activities
-7-889-1,054-31,812-4,887-19,332
Financing Cash Flow
-16,047-16,028-6,85448,329-4,88711,123

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
8481,3622,5383,2433621,583
Miscellaneous Cash Flow Adjustments
2-----
Net Cash Flow
-11,848-11,904-16,797-17,4926,47020,079

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
5,013-3,116-8,244-6,0779,6756,902
Free Cash Flow Growth
----40.18%50.70%
Free Cash Flow Margin
14.12%-10.52%-28.59%-47.60%62.14%38.97%
Free Cash Flow Per Share
55.20-34.52-91.87-73.65117.1484.17
Levered Free Cash Flow
-4,310-2,529-9,249-11,530-1,3678,544
Unlevered Free Cash Flow
-186.38-2,001-8,768-11,038-946.58,868

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
638531435241171157
Cash Income Tax Paid
289-1,0072691,394262-87
Change in Working Capital
-1,7905,306-7,0732,5084,8852,018